Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyalodisc
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Intradiscal
01
Overview
**Hyalodisc** is a hyaluronic acid-based intradiscal injection formulation (8 mg/mL) designed for X-ray-guided administration into the intervertebral disc. It acts as a viscosupplement, mimicking the viscoelastic properties of natural hyaluronic acid in synovial fluid to provide lubrication, shock absorption, and structural support within the disc, potentially alleviating pain associated with degenerative disc disease. Evaluated in clinical investigation NCT04757038, it is combined with PEP (positioning and exercise program) to assess efficacy in disc-related back pain, targeting patients unresponsive to conservative therapies.[6]
- Brand names
- Hyalodisc
02
Targets
HMMRCD44 (CD44 antigen)
Beyond the preview
Go deeper on Hyalodisc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hyalodisc.